# US 2006/0079695 A1 · Antibacterial oxalidinones

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0079695 A1
- Document ID: US20060079695A1
- Status: Published application
- Kind: A1
- Application number: 10/550,038
- Filed: 2004-03-16
- Published: 2006-04-13
- Earliest claimed: 2003-03-20
- Assignees: AstraZeneca AB
- Inventors: Michael Gravestock; Neil Hales; Sheila Hauck
- Web page: https://patentgrep.com/patent/US20060079695A1

## CPC

- C07D 413/14: containing three or more hetero rings
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Compounds of the formula (I), or a pharmaceutically-acceptable salts, or in-vivo-hydrolysable esters thereo Formula (1): wherein N-HeT is for example triazolyl; Q is for example phenyl or pyridyl, substituted withr; T is for example selected from (TAa1 to TAa12) such as (TAa1) and (TAa5): R4h, R5h, R6h are for example selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxy-carbonyl, (1-4C)alkanoyl and carbamoyl; processes for making them, compositions containing them and their use as antibacterial agents are described.

## Claims

### Claim 1

A compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof,
wherein —N-HET is selected from the structures (Ia) to (If) below:—
Q is selected from Q1 to Q6:—
R2 and R3 are independently selected from H, F, Cl, CF3, OMe, SMe, Me and Et; B1 is O or S;
T is selected from the groups in (TAa1) to (TAa12):
wherein:
R6h is selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxycarbonyl, (1-4C)alkanoyl, carbamoyl and cyano;
R4h and R5h are independently selected from hydrogen, halo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (1-4C)alkylS(O)q-(q is 0, 1 or 2), (1-4C)alkanoyl, (1-4C)alkoxycarbonyl, benzyloxy-(1-4C)alkyl, (2-4C)alkanoylamino, —CONRcRv and —NRcRv wherein any (1-4C)alkyl group contained in the preceding values for R4h and R5h is optionally substituted by up to three substituents independently selected from hydroxy (not on C1 of an alkoxy group, and excluding geminal disubstitution), oxo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (2-4C)alkanoyloxy, hydroxyimino, (1-4C)alkoxyimino, (1-4C)alkylS(O)q-(q is 0, 1 or 2), (1-4C)alkylSO2-NRv—, (1-4C)alkoxycarbonyl, —CONRcRv, and —NRcRv (not on C1 of an alkoxy group, and excluding geminal disubstitution); wherein Rv is hydrogen or (1-4C)alkyl and Rc is as hereinafter defined;
R4h and R5h may further be independently selected from (1-4C)alkyl {optionally substituted by one, two or three substituents independently selected from hydroxy (excluding geminal disubstitution), oxo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (2-4C)alkanoyloxy, phosphoryl [—O-P(O)(OH)2, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [—O-P(OH)2 and mono- and di-(1-4C)alkoxy derivatives thereof], hydroxyimino, (1-4C)alkoxyimino, (1-4C)alkylS(O)q-(q is 0, 1 or 2), (1-4C)alkylSO2-NRv—, (1-4C)alkoxycarbonyl, —CONRcRv, —NRcRv (excluding geminal disubstitution), ORc, and phenyl (optionally substituted by one, two or three substituents independently selected from (1-4C)alkyl, (1-4C)alkoxy and halo)}; wherein Rv is hydrogen or (1-4C)alkyl and Rc is as hereinafter defined; and wherein any (1-4C)alkyl group contained in the immediately preceding optional substituents (when R4h and R5h are independently (1-4C)alkyl) is itself optionally substituted by up to three substituents independently selected from hydroxy (not on C1 of an alkoxy group, and excluding geminal disubstitution), oxo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (2-4C)alkanoyloxy, hydroxyimino, (1-4C)alkoxyimino, (1-4C)alkylS(O)q-(q is 0, 1 or 2), (1-4C)alkylSO2-NRv—, (1-4C)alkoxycarbonyl, —CONRcRv, and —NRcRv (not on C1 of an alkoxy group, and excluding geminal disubstitution); wherein Rv is hydrogen or (1-4C)alkyl and Rc is as hereinafter defined;
or R4h is selected from one of the groups in (TAaa) to (TAab) below, or (where appropriate) one of R4h and R5h is selected from the above list.of R4h and R5h values, and the other is selected from one of the groups in (TAaa) to (TAab) below:—
(TAaa) a group of the formula (TAaa1)
wherein Z0 is hydrogen or (1-4C)alkyl;
X0 and Y0 are independently selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxycarbonyl, halo, cyano, nitro, (1-4C)alkylS(O)q-(q is 0, 1 or 2), RvRwNSO2—, trifluoromethyl, pentafluoroethyl, (1-4C)alkanoyl and —CONRvRw [wherein Rv is hydrogen or (1-4C)alkyl;
Rw is hydrogen or (1-4C)alkyl];
(TAab) an acetylene of the formula —≡—H or —≡—(1-4C)alkyl;
wherein Rc is selected from groups (Rc1) to (Rc2) :—
(Rc1) (1-6C)alkyl {optionally substituted by one or more (1-4C)alkanoyl groups (including geminal disubstitution) and/or optionally monosubstituted by cyano, (1-4C)alkoxy, trifluoromethyl, (1-4C)alkoxycarbonyl, phenyl (optionally substituted as for AR1 defined hereinafter), (1-4C)alkylS(O)q-(q is 0, 1 or 2); or, on any but the first carbon atom of the (1-6C)alkyl chain, optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy and fluoro, and/or optionally monosubstituted by oxo, —NRvRw [wherein Rv is hydrogen or (1-4C)alkyl; Rw is hydrogen or (1-4C)alkyl], (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylS(O)pNH— or (1-4C)alkylS(O)p-((1-4c)alkyl)N— (p is 1 or 2)};
(Rc2) R13CO—, R13SO2— or R13CS—
wherein R13 is selected from (Rc2a) to (Rc2d):—
(Rc2a) hydrogen, (1-4C)alkoxycarbonyl, trifluoromethyl and —NRvRw [wherein Rv is hydrogen or (1-4C)alkyl; Rw is hydrogen or (1-4C)alkyl];
(Rc2b) (1-10C)alkyl
{optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkanoyl, carboxy, phosphoryl [—O-P(O)(OH)2, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [—O-P(OH)2 and mono- and di-(1-4C)alkoxy derivatives thereof], and amino; and/or optionally substituted by one group selected from phosphonate [phosphono, —P(O)(OH)2, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphinate [—P(OH)2 and mono- and di-(1-4C)alkoxy derivatives thereof], cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylaminocarbonyl, di((1-4C)alkyl)aminocarbonyl, (1-4C)alkylS(O)pNH—, (1-4C)alkylS(O)p-((1-4C)alkyl)N—, fluoro(1-4C)alkylS(O)pNH—, fluoro(1-4C)alkylS(O)p((1-4C)alkyl)N—, (1-4C)alkylS(O)q— [the (1-4C)alkyl group of (1-4C)alkylS(O)q— being optionally substituted by one substituent selected from hydroxy, (1-4C)alkoxy, (1-4C)alkanoyl, phosphoryl [—O-P(O)(OH)2, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [—O-P(OH)2 and mono- and di-(1-4C)alkoxy derivatives thereof], amino, cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, carboxy, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylaminocarbonyl, di((1-4C)alkyl)aminocarbonyl, (1-4C)alkylS(O)pNH—, (1-4C)alkylS(O)p-((1-4C)alkyl)N—, and (1-4C)alkylS(O)q-;
(Rc2c) R14C(O)O(1-6C)alkyl wherein R14 is AR1, AR2, (1-4C)alkylamino (the (1-4C)alkyl group being optionally substituted by (1-4C)alkoxycarbonyl or by carboxy), benzyloxy-(1-4C)alkyl or (1-10C)alkyl {optionally substituted as defined for (Rc2b)};
(Rc2d) R15O— wherein R15 is benzyl, (1-6C)alkyl {optionally substituted as defined for (Rc2c)} or AR2b;
wherein
AR1 is an optionally substituted phenyl or optionally substituted naphthyl;
AR2 is an optionally substituted 5- or 6-membered, fully unsaturated monocyclic heteroaryl ring containing up to four heteroatoms independently selected from O, N and S (but not containing any O13 O, O—S or S—S bonds), and linked via a ring carbon atom, or a ring nitrogen atom if the ring is not thereby quaternised;
AR2a is a partially hydrogenated version of AR2, linked via a ring carbon atom or linked via a ring nitrogen atom if the ring is not thereby quaternised;
AR2b is a fully hydrogenated version of AR2, linked via a ring carbon atom or linked via a ring nitrogen atom.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Q is Q1.

### Claim 3 (depends on 1)

The compound of claim 1, wherein —N-HET is 1,2,3-triazol-1-yl or tetrazol-2-yl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R2 and R3 are independently hydrogen or fluoro.

### Claim 5 (depends on 1)

The compound of claim 1, wherein T is selected from TAa1 to TAa4, TAa5, TAa7 and TAa8.

### Claim 6 (depends on 1)

The compound of claim 1, which is a compound of formula (IB
wherein —N-HET is 1,2,3-triazol-1-yl or tetrazol-2-yl;
R2 and R3 are independently hydrogen or fluoro;
T is selected from TAa1, TAa5, TAa7 and TAa8;
R6h is hydrogen or (1-4C)alkyl;
R4h and R5h are independently selected from hydrogen, cyano, hydroxy(1-4C)alkyl, cyano(1-4C)alkyl, phosphoryl(1-4C)alkyl, benzyl (optionally substituted on the phenyl ring by one substituent selected from halo, methyl and methoxy), (1-4C)alkyl, (1-4C)alkyl substituted with ORc (wherein Rc is R13CO and R13 is selected from Rc2b), (1-4C)alkanoyl and (1-4C)alkoxycarbonyl.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

A method for producing an antibacterial effect in a warm blooded animal which comprises administering to said animal an effective amount of a compound of claim 1.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A pharmaceutical composition which comprises a compound of claim 1, and a pharmaceutically-acceptable diluent or carrier.

### Claim 12 (depends on 1)

A process for the preparation of a compound of formula (I) as claimed in claim 1 or pharmaceutically acceptable salts or in-vivo hydrolysable esters or pro-drugs thereof, which process comprises one of processes (a) to (g):
(a) by modifying a substituent in, or introducing a new substituent into, the substituent group Q of another compound of formula (I); or
(b) by reaction of a compound of formula (II):
wherein Y is a displaceable group with a compound of the formula (III):
—N-HET (III)
wherein —N-HET (of formula (Ia) to (If) optionally protected) is HN-HET (free-base form) or —N-HET anion formed from the free base form; or
(c) by reaction of a compound of the formula (IV)
Q-Z (IV)
wherein Z is an isocyanate, amine or urethane group with an epoxide of the formula (V) wherein the epoxide group serves as a leaving group at the terminal C-atom and as a protected hydroxy group at the internal C-atom; or with a related compound of formula (VI) where
the hydroxy group at the internal C-atom is protected and where the leaving group Y at the terminal C-atom is a leaving group;
or
(d) (i) by coupling, using catalysis by transition metals, of a compound of formula (VII):
wherein Y′ is a group —N-HET as hereinbefore defined, X is a replaceable substituent; with a compound of the formula (VIII), or an analogue thereof, which is suitable to give a T substituent as defined by (TAa1-TAa12) in which the link is via an sp2 carbon atom (D═CH═C-Lg where Lg is a leaving group; or as in the case of reactions carried out under Heck reaction conditions Lg may also be hydrogen)
where T1 and T2 may be the same or different and comprise a precursor to a ring of type T as hereinbefore defined, or T1 and T2 may together with D form a ring of type T as hereinbefore defined;
(d) (ii) by coupling, using catalysis by transition metals, of a compound of formula (VIIA):
wherein Y′ is a group HET as hereinbefore defined, with a compound
[Aryl]-X
where X is a replaceable substituent;
(e) Where N-HET is 1,2,3-triazole by cycloaddition via the azide (wherein Y in (II) is azide), with acetylene or masked acetylene;
(f) Where N-HET is 1,2,3-triazole by synthesis with a compound of formula (IX), namely the arenesulfonylhydrazone of acetaldehyde, by reaction of a compound of formula (II) where Y=NH2 (primary amine);
(g) Where N-HET is 1,2,3-triazole by cycloaddition via the azide (wherein Y in (II) is azide) with acetylene using Cu(I) catalysis in to give the N-1,2,3-triazole;
and thereafter if necessary:
i) removing any protecting groups;
ii) forming a pro-drug (for example an in-vivo hydrolysable ester); and/or
iii) forming a pharmaceutically-acceptable salt.

### Claim 13

A compound which is
(5R)-3-[3-Fluoro-4-(3-methylisoxazol-5-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;
Ethyl 5-{2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}isoxazole-3-carboxylate;
(5R)-3-{3-Fluoro-4-[3-(hydroxymethyl)isoxazol-5-yl]phenyl}-5-(1 H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;
(5-{2-Fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}isoxazol-3-yl)methyl dihydrogen phosphate;
1-Methyl-3-{4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}-1 H-pyrazole-5-carbonitrile;
1-Methyl-3-{4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}-1 H-pyrazole-5-carbaldehyde;
(5R)-3-[3-Fluoro-4-(1H-1,2,3-triazol-4-yl)phenyl]-5-(1 H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;
(5R)-3-[3-Fluoro-4-(1-methyl-1 H-1,2,3-triazol-4-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;
(5R)-3-[3-Fluoro-4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl]-5-( 1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;
(4-{2-Fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol- 1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}-1H-1,2,3-triazol-1-yl)acetonitrile; or
(4-{2-Fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}-2H-1,2,3-triazol-2-yl)acetonitrile.
